Calcium ions (Ca) are indispensable and versatile metal ions that play a pivotal role in regulating cell metabolism, encompassing cell survival, proliferation, migration, and gene expression. Aberrant Ca levels are frequently linked to cell dysfunction and a variety of pathological conditions. Therefore, it is essential to maintain Ca homeostasis to coordinate body function. Disrupting the balance of Ca levels has emerged as a potential therapeutic strategy for various diseases, and there has been extensive research on integrating this approach into nanoplatforms. In this review, the current nanoplatforms that regulate Ca homeostasis for cancer therapy are first discussed, including both direct and indirect approaches to manage Ca overload or inhibit Ca signalling. Then, the applications of these nanoplatforms in targeting different cells to regulate their Ca homeostasis for achieving therapeutic effects in cancer treatment are systematically introduced, including tumour cells and immune cells. Finally, perspectives on the further development of nanoplatforms for regulating Ca homeostasis, identifying scientific limitations and future directions for exploitation are offered.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10867402 | PMC |
http://dx.doi.org/10.1002/EXP.20230019 | DOI Listing |
Neoplasia
December 2024
Felsenstein Medical Research Center, Beilinson Campus, Petah Tikva, Israel; Tel Aviv University, Faculty of Medicine and Health Sciences, Tel Aviv, Israel; Rabin Medical Center, Beilinson Campus, Petah Tikva, Israel; Davidoff Cancer Center, Beilinson Campus, Petah Tikva, Israel. Electronic address:
Triple-negative breast cancer (TNBC) is an aggressive subtype that accounts for 10-15 % of breast cancer. Current treatment of high-risk early-stage TNBC includes neoadjuvant chemo-immune therapy. However, the substantial variation in immune response prompts an urgent need for new immune-targeting agents.
View Article and Find Full Text PDFCurr Opin Obstet Gynecol
October 2024
Department of Medicine, Palliative Care, University of California at Los Angeles, Los Angeles CA, USA.
Purpose Of Review: This review assesses the impact of early integration of palliative care and the disparities that exist among patients with gynecologic malignancies. It also highlights the recent advances in symptom management, goals of care communication, and end of life care.
Recent Findings: Although palliative care has been utilized earlier, there are still barriers to its integration both nationally and worldwide, manifesting as predominantly late hospice referrals and aggressive care at the end of life.
Blood
December 2024
Versiti Blood Research Institute, Milwaukee, Wisconsin, United States.
Starting with imatinib, tyrosine kinase inhibitors (TKIs) have turned chronic myeloid leukemia (CML) from a lethal blood cancer into a chronic condition. As patients with access to advanced CML care have an almost normal life expectancy, there is a perception that CML is a problem of the past, and one should direct research resources elsewhere. However, a closer look at the current CML landscape reveals a more nuanced picture.
View Article and Find Full Text PDFPLoS One
December 2024
Department of Pharmacy, The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
Drug resistance of cancers remains a major obstacle due to limited therapeutics. Lysosome targeting is an effective method for overcoming drug resistance in cancer cells. St-N (ent-13-hydroxy-15-kaurene-19-acid N-methylpiperazine ethyl ester) is a novel alkaline stevioside derivative with an amine group.
View Article and Find Full Text PDFBlood Adv
December 2024
The University of Texas, MD Anderson Cancer Center, Houston, Texas, United States.
We investigated BCMA-directed CART in patients with relapsed or refractory multiple myeloma (RRMM) and CNS involvement. Ten patients who received either ide-cel (n=6) or cilta-cel (n=4) were included in this analysis. Patients had brain/cranial nerve and/or spinal cord involvement/leptomeningeal disease evident on either MRI (100%) and/or CSF (40%).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!